SCHEMBL30656795

SCHEMBL30656795

COCCn1cnc2ccc(N)c(-c3ccc(F)cc3)c2c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 1/20 0.41
CYP1A2 P05177 8/20 0.41
CYP3A4 P08684 5/20 0.41
USP2 O75604 5/20 0.41
ALDH1A1 P00352 8/20 0.40
HSD17B10 Q99714 8/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
CASP1 P29466 5/20 0.39
CASP7 P55210 5/20 0.39
CYP2C9 P11712 4/20 0.39
CYP2D6 P10635 2/20 0.39
GLA P06280 2/20 0.39
PIK3CA P42336 1/20 0.38
PIK3CB P42338 1/20 0.38
RXFP1 Q9HBX9 1/20 0.37
NPC1 O15118 2/20 0.37
HPGD P15428 2/20 0.37
RAB9A P51151 2/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24165960 1.00 BRAF (0.41) BRAFCYP1A2CYP3A4USP2ALDH1A1
SCHEMBL24166480 0.89 ALOX15 (0.46) CYP1A2CYP3A4USP2ALDH1A1HSD17B10
SCHEMBL30656834 0.89 ALOX15 (0.46) CYP1A2CYP3A4USP2ALDH1A1HSD17B10
SCHEMBL30656811 0.89 ALDH1A1 (0.43) BRAFCYP1A2CYP3A4ALDH1A1HSD17B10
SCHEMBL24166503 0.89 ALDH1A1 (0.43) BRAFCYP1A2CYP3A4ALDH1A1HSD17B10
SCHEMBL24166466 0.88 NR3C1 (0.39) BRAFALDH1A1HSD17B10KMT2AMEN1
SCHEMBL30656808 0.88 NR3C1 (0.39) BRAFALDH1A1HSD17B10KMT2AMEN1
SCHEMBL24166155 0.88 KMT2A (0.40) BRAFALDH1A1HSD17B10KMT2AMEN1
SCHEMBL30656856 0.88 KMT2A (0.40) BRAFALDH1A1HSD17B10KMT2AMEN1
SCHEMBL24166156 0.84 PIK3CA (0.43) BRAFALDH1A1HSD17B10KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528777-B2 Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2026-01-20 US disclosed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF ATG7, GOT1, LIPC BRAF 4469/4885CYP1A2 362/4885CYP3A4 433/4885
US-12528777-B2 Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof ATG7, GOT1, ULK1 BRAF 4381/4885CYP1A2 1581/4885CYP3A4 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.